Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 6/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | NRP1 | O14786 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13359253 | 0.85 | LMNA (0.49) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL13614191 | 0.82 | LMNA (0.47) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL14968743 | 0.79 | LMNA (0.56) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL6098517 | 0.75 | LMNA (0.61) | LMNAKDM4E | |
| SCHEMBL20381145 | 0.74 | LMNA (0.43) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL12824692 | 0.74 | LMNA (0.43) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL12741150 | 0.73 | LMNA (0.43) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL12922882 | 0.73 | LMNA (0.43) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL1641716 | 0.72 | TDP1 (0.45) | LMNATDP1NLRP3KDM4ES1PR1 | |
| SCHEMBL2702033 | 0.72 | TDP1 (0.45) | LMNATDP1NLRP3KDM4ES1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | LMNA 75/4885TDP1 3499/4885NLRP3 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.